Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070187 · ClinicalTrials.gov registry record · Phase 2
Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
A Phase 2 study of Lymphoma, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 20
- Study locations
NCT00070187 is a Phase 2 study of Lymphoma that has completed, run by Children's Oncology Group. The registered enrollment target is 24 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT00070187, a Phase 2 study of Lymphoma, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving immunotherapy using cyclosporine, interferon gamma, and interleukin-2 after stem cell transplantation may help the transplanted cells make an immune response and kill any remaining cancer cells. It is not yet known whether high-dose chemotherapy followed by autologous stem cell transplantation is more effective with or without immunotherapy. PURPOSE: This randomized phase II/III trial is studying how well high-dose chemotherapy followed by autologous stem cell transplantation, cyclosporine, interferon gamma, and interleukin-2 works and compares it to high-dose chemotherapy followed by autologous stem cell transplantation only in treating patients with refractory or relapsed Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG carmustine
- BIOLOGICAL aldesleukin
- BIOLOGICAL filgrastim
- DRUG cyclosporine
- BIOLOGICAL recombinant interferon gamma
Study Locations (20)
Florida
- University of Florida Shands Cancer Center - Gainesville
- Nemours Children's Clinic - Jacksonville
- University of Miami Sylvester Comprehensive Cancer Center - Miami
- Miami Children's Hospital - Miami
- All Children's Hospital - St. Petersburg
- St. Joseph's Cancer Institute at St. Joseph's Hospital - Tampa
- Kaplan Cancer Center at St. Mary's Medical Center - West Palm Beach
California
- Jonsson Comprehensive Cancer Center at UCLA - Los Angeles
- Children's Hospital and Research Center - Oakland - Oakland
- Children's Hospital of Orange County - Orange
- Kaiser Permanente Medical Center - Oakland - Sacramento
Illinois
- Children's Memorial Hospital - Chicago - Chicago
- Southern Illinois University School of Medicine - Springfield
Alabama
- Comprehensive Cancer Center at University of Alabama at Birmingham - Birmingham
Arizona
- Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Delaware
- Alfred I. duPont Hospital for Children - Wilmington
District of Columbia
- Children's National Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2003-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070187
The ClinicalTrials.gov registry entry for NCT00070187 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which carmustine is the first listed.
NCT00070187 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00070187 about?
NCT00070187 is a clinical study titled "Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving immunotherapy u...
What is the current status of trial NCT00070187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2003-11.
What conditions does trial NCT00070187 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00070187?
The interventions under investigation include: carmustine (DRUG), aldesleukin (BIOLOGICAL), filgrastim (BIOLOGICAL), cyclosporine (DRUG), recombinant interferon gamma (BIOLOGICAL).
Who is sponsoring clinical trial NCT00070187?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00070187 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.